Genfit Delays NASH Data While It Confers With US FDA On Methodology

 
• By Joseph Haas

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.

Data Collection - Three Arrows Hit in Red Target
Genfit will await FDA insight on statistical methodology before unblinding its Phase III NASH study

More from Clinical Trials

More from R&D